HB-adMSCs for Acute Kidney Injury

About Hope Biosciences

Hope Biosciences operates a dual business model combining consumer-facing stem cell banking with a therapeutic development pipeline. Its proprietary technology platform enables the large-scale, consistent expansion and cryopreservation of autologous and allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs). The company is advancing these cells through clinical trials for conditions like Multiple System Atrophy and Acute Kidney Injury, positioning itself in the growing regenerative medicine market. As a private company, it appears to be in a pre-revenue or early-revenue stage, funding operations and research through its banking services and potentially grants/foundation work.

Therapeutic Areas